INMB logo

INMB INmune Bio, Inc.

NASDAQ Capital Market · Biotechnology · Healthcare

$0.83
-0.07 (-7.50%)

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory …

Market Cap: $25.60Mwww.inmunebio.com

Price

No data yet.

Social Signal Score

46
5d
—
30d
43
3 mentions
—
60d
46
5 mentions
—
90d
49
6 mentions
—
news: 6

Analyst Ratings

9 analysts
Buyconsensus
Strong Buy 0Buy 6Hold 2Sell 1Strong Sell 0
Avg price target$22+2560.2%
Low $22Median $22High $22
Current Consensus

Revenue

$0.00
$0.00$54.3K$108.7K$163.0K
Dec 2016Sep 2026

Analyst Estimates

FY2025
$-1.93
$-3.92–$0.06
1 analysts
FY2026
$-0.63
$-1.27–$0.02
2 analysts
FY2027
$-0.71
$-1.45–$0.02
1 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
David J. Moss
Sector
Healthcare
Industry
Biotechnology
Employees
21
Beta
0.94
Country
US
Piotroski score
2 / 9 (Weak)
Altman Z-score
-11.55
www.inmunebio.com